Fentanyl and Clonidine for Analgesia During Hypothermia in Term Asphyxiated Infants (SANNI 1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03177980|
Recruitment Status : Recruiting
First Posted : June 6, 2017
Last Update Posted : December 10, 2019
|Condition or disease||Intervention/treatment|
|Asphyxia Neonatorum||Drug: Fentanyl Drug: Fentanyl and clonidine|
All patients that are admitted to the study neonatal intensive care units (NICUs) for hypothermic treatment due to perinatal asphyxia are potential study patients, and their parents will be asked for consent.
The patient will be treated according to clinical guidelines and will be included in the study if in need for fentanyl and clonidine according to clinical judgment (HIE and pain scores) and as decided by the responsible clinical doctor. The dosing and administration of the drugs will be implemented according to an algorithm based on pain scoring results.
Apart from extra blood sampling, the bedside monitoring, investigations (electroencephalography (EEG), echocardiography (ECG), ultrasound of the brain and magnetic resonance imaging, (MRI)) and follow-up (neurologic examination) are the same as for all infants receiving hypothermia according to national and international guidelines. A brief standardised pain stimulation will be performed as part of the pain and stress assessment.
In total 50 infants will be included.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Fentanyl and Clonidine for Analgesia During Hypothermia in Term Asphyxiated Infants - a Prospective Pharmacokinetic/Pharmacodynamic/Pharmacogenetic Observational Study. Cohort 1 in The SANNI Project.|
|Actual Study Start Date :||April 24, 2017|
|Estimated Primary Completion Date :||August 30, 2020|
|Estimated Study Completion Date :||December 31, 2021|
All infants in need of analgesia according to an algorithm based on pain assessment results will receive fentanyl as the first analgesic drug.
The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
Fentanyl and Clonidine
Infants in need of further analgesia according to an algorithm based on pain assessment results will receive fentanyl and clonidine as the analgesic drugs.
Drug: Fentanyl and clonidine
In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
- Pharmacokinetics (PK) of fentanyl and clonidine [ Time Frame: Repeated blood samples over a total of 4 - 7 days] ]Analysed with NONMEM (Non-linear Mixed Effect Modelling) populationbased PK statistics
- Neurophysiologic response; by single cortical events and their dynamics in relation to PK [ Time Frame: From admission to the department until 4- 72 h after reaching normothermia.] ]Analyse of single cortical events and their dynamics based on burst detection and measuring features of individual bursts as well as their mass statistical behaviour over time.
- Neurophysiologic response; longer term brain function in relation to PK [ Time Frame: From admission to the department until 4- 72 h after reaching normothermia ]Assessment of longer term brain function using measures of long range correlation and brain activity cycling.
- Neurophysiologic response; global brain network function in relation to PK [ Time Frame: From admission to the department until 4- 72 h after reaching normothermia ]Assessment of global brain network function will be based on Activation Synchrony Index.
- Change in/association between physiological parameters (heart rate, blood pressure, peripheral oxygen saturation and NIRS (near-infrared reflectance spectroscopy near-infrared spectroscopy) parameters) in relation to PK parameters [ Time Frame: From admission to the department until 4- 72 h after reaching normothermia. ]
- Change in pain responses as measured by pain assessment score for continuous pain/stress (ALPS-Neo and Comfort Neo) in relation to PK [ Time Frame: From admission to the department until 4- 72 h after reaching normothermia. ]
- Procedural pain response at a short standardized pain stimulation; as assessed with change in galvanic skin response, change in serum-cortisol and scored by a procedural pain assessment scale (PIPP-R) in relation to PK. [ Time Frame: Once during stable treatment with hypothermia and 6 hours of unchanged medication ]
- Pharmacogenetic profile in relation to PK and PD results; how PK/PD phenotypes depend on pharmacogenetic (PG) profiles. [ Time Frame: One blood sample during study ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03177980
|Contact: Elisabeth Norman, MD||+46 email@example.com|
|Skåne Uniersity Hospital||Recruiting|
|Lund, Sweden, 221 85|
|Contact: Elisabeth Norman, MD, PhD +46 705594340 firstname.lastname@example.org|
|Principal Investigator: Elisabeth Norman, MD, PhD|
|Karolinska University Hospital||Not yet recruiting|
|Stockholm, Sweden, 171 76|
|Contact: Boubou Hallberg, MD, PhD + 46 70 002 10 10 email@example.com|
|Principal Investigator: Boubou Hallberg, MD, PhD|
|Principal Investigator:||Elisabeth Norman, MD||Region Skane and Lunds University|